| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Deleted in lung and esophageal cancer protein 1, Deleted in lung cancer protein 1, DLC-1, DLEC1 {ECO:0000312|EMBL:BAA776241} |
| Entrez GeneID | 9940 |
| WB Predicted band size | 195.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This DLEC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 879-908 amino acids from the Central region of human DLEC1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DLEC1抗体的3篇文献示例(注：以下内容为模拟概括，实际文献需通过学术数据库查询)：
1. **文献名称**：*DLEC1 expression is silenced by DNA methylation in lung cancer*
**作者**：Wang Y, et al.
**摘要**：该研究通过免疫组化(使用DLEC1特异性抗体)及甲基化分析，发现DLEC1在非小细胞肺癌组织中表达显著降低，且其启动子高甲基化是导致表达缺失的主要原因，提示DLEC1可作为肺癌的潜在表观遗传生物标志物。
2. **文献名称**：*Antibody-based detection of DLEC1 in ovarian cancer and its prognostic significance*
**作者**：Chen L, et al.
**摘要**：研究利用DLEC1单克隆抗体对卵巢癌组织进行染色，发现DLEC1蛋白表达缺失与患者不良预后显著相关，并通过体外实验证实DLEC1通过调控细胞周期抑制肿瘤生长。
3. **文献名称**：*Epigenetic inactivation of DLEC1 in nasopharyngeal carcinoma: A study using antibody-mediated protein localization*
**作者**：Zhang H, et al.
**摘要**：通过Western blot和免疫组化(基于DLEC1抗体)分析鼻咽癌样本，发现DLEC1蛋白表达下调与肿瘤分期和转移相关，且其表达缺失主要由基因启动子甲基化引起。
如需具体文献，建议通过PubMed或Google Scholar以“DLEC1 antibody”及“DLEC1 cancer”为关键词检索，并筛选近五年内的高影响力期刊研究。
DLEC1 (Deleted in Lung and Esophageal Cancer 1) is a tumor suppressor gene located on chromosome 3p21.3. a region frequently deleted or epigenetically silenced in various cancers, including lung, esophageal, ovarian, and gastrointestinal tumors. The DLEC1 protein is implicated in regulating cell proliferation, apoptosis, and cytoskeletal organization, though its precise molecular mechanisms remain under investigation. Loss of DLEC1 expression, often due to promoter hypermethylation or chromosomal deletions, is associated with cancer progression and poor prognosis.
Antibodies targeting DLEC1 are primarily used in research to detect its expression in tissues or cell lines, aiding in studies of its role in carcinogenesis and potential therapeutic applications. These antibodies enable techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to visualize DLEC1 localization and quantify its levels in normal versus cancerous tissues. Commercial DLEC1 antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing.
Despite its established tumor-suppressive role, DLEC1's functional pathways and interactions are not fully elucidated. Ongoing research focuses on its involvement in signaling cascades, such as Wnt/β-catenin or p53 pathways, and its utility as a biomarker for early cancer detection or monitoring treatment response. DLEC1 antibodies thus serve as critical tools for unraveling its biological significance and clinical relevance in oncology.
×
